Clinical Profile of Retinal Vein Occlusion in Hospital Universiti Sains Malaysia – 7 Years Review

Khairul-Anwar Ibrahim, Abdul-Hadi Rosli, Mutasim Hassan, Zunaina Embong

Abstract


To review the clinical profile of retinal vein occlusion (RVO) in Hospital Universiti Sains Malaysia (USM) from 2011 until 2017. This was a retrospective single-centre case series. The medical records of the patients presented to Ophthalmology Clinic with RVO from 2011 to 2017 were reviewed. A total of 24 patients (26 eyes) with a diagnosis of RVO in Hospital USM were reviewed. There was 91.6% of our patients were aged more than 45 years old with predominantly affected male gender (58.3%). Majority of the patients were Malays (87.5%). Hypertension (70.8%), hyperlipidemia (70.8%) and diabetes mellitus (54.2%) were the common systemic comorbidities in RVO patients. Majority of the patients (87.5%) were non-smoker. Based on type of RVO, there were 38.5% central RVO, 26.9% branch RVO, 19.2% macular branch RVO, and 15.4% hemivein occlusion. RVO was bilateral in 2 patients (8.4%). Based on fundus fluorescein angiography, 3 patients (11.5%) showed ischaemic features. Reduce vision (91.6%) was the main presenting symptoms of RVO while intraretinal haemorrhage (100%) and macular oedema (96.2%) were the most common ocular signs found in RVO. There were 16 eyes (61.5%) have visual acuity equal or better than 6/60 at presentation. Patient who had visual acuity equal or better than 6/60 showed promising improvement in visual acuity post treatment. Elderly with multiple comorbidities complaining of worsening of vision should have high index suspicion of RVO. Presenting visual acuity is associated with final visual outcome post treatment


Keywords


Retinal vein occlusion, macular oedema, fundus fluorescein angiography.

Full Text:

PDF

References


Klein R, Barbar EK, Moss SE, Meuer SM, Klein BEK. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126(4): 513-518. Doi: 10.1001/archopht.126.4.513.

Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: The Blue Mountains Eye Study. Arch. Ophthalmol. 1996; 114 (10): 1243–1247. Doi: 10.1001/archopht.1996.01100140443012.

Garcia-Arumi J, Gómez-Ulla F, Amparo N, Cervera E, Fonollosa A. Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naïve patients with macular oedema secondary to central retinal vein occlusion (CRVO): A prospective 12-month, single-arm, multicentre trial. J Ophthalmol. 2018; 8310350. Doi: 10.1155/2018/8310350.

Lim LL, Cheung N, Wang JJ, Islam FM, Mitchell P, Saw SM, et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008; 92(10): 1316-1319. Doi: 10.1136/bjo.2008.140640.

Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: The Hisayama Study. Invest Ophthalmo Vis Sci. 2010; 51(6): 3205-3209. Doi: 10.1167/iovs.09-4453.

Rehak J, Rehak M. Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008; 33 (2): 111-131. Doi: 10.1080/02713680701851902.

Shroff D, Kothari A, Bhatia G, Gupta C. Clinical Diagnosis of retinal vein occlusion. Int J Ophthalmic Res. 2016; 2(2): 137-142.

Hayreh SS, Zimmerman MB. Branch retinal vein occlusion: Natural history of visual outcome. JAMA Ophthalmol. 2014; 132 (1): 13-22. Doi: 10.1001/jamaophthalmol.2013.5515.

The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996; 114: 545–554.

Wang M, Khurana RN, Sadda SR. Central retinal vein occlusion in Wegener’s granulomatosis without retinal vasculitis. Br J Ophthalmol. 2006; 90(11): 1435-1436. Doi: 10.1136/bjo.2006.095703.

Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol. 2017; 11: 441-447. Doi: 10.2147/OPTH.S128341. Ecollection 2017.

Retinal Vein Occlusion RVO Guidelines. Royal College of Ophthalmologists 2015.

Ko J, Kwon OW, Byeon SH. Optical coherence tomography predicts visual outcome in acute central retinal vein occlusion. Retina. 2014; 34: 1132-1141.

Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2011; 5: 705-713.

Kida T. Mystery of retinal vein occlusion: Vasoactivity of the vein and possible involvement of endothelin-1. Biomed Res Int. 2017; 1–16. Https://doi.org/10.1155/2017/4816527.

Chen YY, Sheu SJ, Hu HY, Chu D, Chou P. Association between retinal vein occlusion and an increased risk of acute myocardial infarction: A Nationwide Population-based Follow-up Study. Plos ONE. 2017; 12(9: e0184016.

Chen YY, Yen YF, Lin JX, Feng SC, Wei LC, Lai YJ, et al. Risk of ischemic stroke, hemorrhagic stroke, and all-cause mortality in retinal vein occlusion: A Nationwide Population-Based Cohort Study. J Ophthalmol. 2018; 8629429.

Liu W, Xu L, Jonas JB. Vein occlusion in Chinese subjects. Ophthalmology. 2007; 114(9): 1795-1796.

Koh V, Cheung CY, Li X, Tian D, Wang JJ, Mitchell P, et al. Retinal vein occlusion in a multi-ethnic Asian population: The Singapore Epidemiology of Eye Disease Study. Ophthalmic Epidemiol. 2016; 23(1): 6-13. Doi: 10.3109/09286586.2015.1082604.

Shin YU, Cho H, Kim JM, Bae K, Kang MH, Shin JP, et al. Prevalence and associated factors of retinal vein occlusion in the Korean National Health and Nutritional Examination Survey, 2008–2012: A cross-sectional observational study. Medicine (Baltimore). 2016; 95(44). E5185.

O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008; 126: 692–699.

Teoh SL, Amarjeet K. A comparative study of branch retinal vein occlusion and central vein occlusion amongst Malaysian patients. Med J Malaysia. 1993; 48(4): 410-415.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6): 1102-1112.e1.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology. 2010; 117: 1124–1133.e1.

Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016; 169: 258-267.

Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019; 242(3): 123–162.

Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994; 42: 109-132.

Noma H, Shimizu H, Mimura. Unilateral Macular Edema With Central Retinal Vein Occlusion In Systemic Lupus Erythematosus: A Case Report. Clin Ophthalmol. 2013; 7: 865–867.

Calugaru D, Calugaru M. Central Retinal Vein Occlusion In A Young Adult Case Report. Rom J Ophthalmol. 2016; 60(2): 120–124.

Azhan A, Mutasim H, Abdul-Hadi R, Khairul-Anwar I, Zunaina E. Macular branch retinal vein occlusion: A revisit and case report. J of Biomed & Clin Sci. 2018; 3(2); 18-21.




Copyright (c) 2020 Journal of Biomedical and Clinical Sciences (JBCS)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Biomedical and Clinical Sciences (JBCS) publishes original research articles, short review, short communication, case reports, quiz and letter to editor that covering the areas of fundamental aspects of biomedical and clinical sciences, from pre-clinical towards translational research and their applications in medicine, dentistry and healthcare management. JBCS aims to provide a platform for basic science and clinical researchers to communicate and share their research findings to the advancement of technologies in biomedical and clinical sciences by providing maximum access to scholarly communication.

Flag Counter           

                     

                                              Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
                                            Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.